Peptides binding to the dimer interface of thymidylate synthase for the treatment of cancer

The present invention relates to peptides binding to the thymidylate synthase protein, in particular to human thymidylate synthase (hTS) protein, for the treatment of cancer.The present invention relates to peptides that can bind at a binding site located at the interface of thymdylate synthase protein. These peptides range from 3 to 10, preferably 4-8 amino acids and have a sequence that binds to each subunit of the thymidylate synthase dimer at the level of dimer interface, stabilizing the dimeric inactive form of the thymdylate synthase enzyme. In addition, the present invention relates to pharmaceutical compositions comprising these compounds as active agents, and uses thereof for the treatment of cancer and to reverse or/and be active in cancer drug resistance.The present invention relates to peptides binding to the thymidylate synthase protein, m particular to human thymidylate synthase (hTS) protein, for the treatment of cancer. The present invention relates to peptides that can bind at a binding site located at the interface of thymdylate synthase protein. These peptides range from 3 to 10, preferably 4-8 amino acids and have a sequence that binds to each subunit of the thymidylate synthase dimer at the level of dimer interface, stabilizing the dimeric inactive form of the thymdylate synthase enzyme. In addition, the present invention relates to pharmaceutical compositions comprising these compounds as active agents, and uses thereof for the treatment of cancer and to reverse or/and be active m cancer drug resistance